{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:10:37Z","timestamp":1778854237862,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100025520","name":"Medical Research Future Fund","doi-asserted-by":"publisher","award":["2009160"],"award-info":[{"award-number":["2009160"]}],"id":[{"id":"10.13039\/501100025520","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.pathol.2025.12.007","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T07:58:05Z","timestamp":1773129485000},"page":"411-419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness analysis of four sampling and genomic testing strategies for patients with advanced non-small-cell lung cancer in Australia"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3159-4249","authenticated-orcid":false,"given":"Louisa G.","family":"Collins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4816-8289","authenticated-orcid":false,"given":"Peter T.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7471-3041","authenticated-orcid":false,"given":"Daniel","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Nones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberley","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9186-3972","authenticated-orcid":false,"given":"David","family":"Fairbairn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2311-4919","authenticated-orcid":false,"given":"David","family":"Fielding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2025.12.007_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.pathol.2025.12.007_bib2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.pathol.2025.02.001","article-title":"Molecular testing of lung cancer in Australia: consensus best practice recommendations from the Royal College of Pathologists of Australasia in collaboration with the thoracic oncology group of Australasia","volume":"57","author":"Cooper","year":"2025","journal-title":"Pathology"},{"key":"10.1016\/j.pathol.2025.12.007_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lungcan.2022.01.021","article-title":"Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: a contemporary clinical practice patterns study","volume":"167","author":"Paz-Ares","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.pathol.2025.12.007_bib4","article-title":"Impact of clinical practice gaps on the implementation of personalized medicine in advanced non-small-cell lung cancer","volume":"6","author":"Sadik","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.pathol.2025.12.007_bib5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00408-023-00631-9","article-title":"Whole genome sequencing in advanced lung cancer can be performed using Diff-Quik cytology smears derived from endobronchial ultrasound, transbronchial needle aspiration (EBUS TBNA)","volume":"201","author":"Fielding","year":"2023","journal-title":"Lung"},{"key":"10.1016\/j.pathol.2025.12.007_bib6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1159\/000495661","article-title":"Diff-Quik cytology smears from endobronchial ultrasound transbronchial needle aspiration lymph node specimens as a source of DNA for next-generation sequencing instead of cell blocks","volume":"97","author":"Fielding","year":"2019","journal-title":"Respiration"},{"key":"10.1016\/j.pathol.2025.12.007_bib7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/cncy.22690","article-title":"Evaluating Diff-Quik cytology smears for large-panel mutation testing in lung cancer\u2014predicting DNA content and success with low-malignant-cellularity samples","volume":"131","author":"Fielding","year":"2023","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.pathol.2025.12.007_bib8","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1158\/1078-0432.CCR-22-1749","article-title":"A large-scale prospective concordance study of plasma- and tissue-based next-generation targeted sequencing for advanced non-small cell lung cancer (LC-SCRUM-Liquid)","volume":"29","author":"Sugimoto","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2025.12.007_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.19.00002","article-title":"Cost effectiveness of multigene panel sequencing for patients with advanced non-small-cell lung cancer","volume":"3","author":"Steuten","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.pathol.2025.12.007_bib10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2019.11.022","article-title":"Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: incremental yield of actionable alterations and cost-effectiveness analysis","volume":"139","author":"Tan","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.pathol.2025.12.007_bib11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jval.2022.07.006","article-title":"Cost-effectiveness and budget impact of future developments with whole-genome sequencing for patients with lung cancer","volume":"26","author":"Simons","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.pathol.2025.12.007_bib12","article-title":"Cost-effectiveness of parallel versus sequential testing of genetic aberrations for stage IV non-small-cell lung cancer in The Netherlands","volume":"6","author":"Wolff","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.pathol.2025.12.007_bib13","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.3390\/curroncol30020180","article-title":"Cost savings of expedited care with upfront next-generation sequencing testing versus single-gene testing among patients with metastatic non-small cell lung cancer based on current Canadian practices","volume":"30","author":"Sheffield","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.pathol.2025.12.007_bib14","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3390\/cancers16040785","article-title":"Evaluation of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) samples from advanced non-small cell lung cancer for whole genome, whole exome and comprehensive panel sequencing","volume":"16","author":"Fielding","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pathol.2025.12.007_bib15","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.canlet.2015.11.038","article-title":"Rapid on-site evaluation during endobronchial ultrasound-guided transbronchial needle aspiration for the diagnosis of hilar and mediastinal lymphadenopathy in patients with lung cancer","volume":"371","author":"Guo","year":"2016","journal-title":"Cancer Lett"},{"key":"10.1016\/j.pathol.2025.12.007_bib16","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1378\/chest.15-0583","article-title":"Randomized trial of endobronchial ultrasound-guided transbronchial needle aspiration with and without rapid on-site evaluation for lung cancer genotyping","volume":"148","author":"Trisolini","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.pathol.2025.12.007_bib17","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/cncr.32876","article-title":"Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: analysis of over 8000 cases","volume":"126","author":"Mack","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2025.12.007_bib20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1471-2288-11-139","article-title":"Improved curve fits to summary survival data: application to economic evaluation of health technologies","volume":"11","author":"Hoyle","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.pathol.2025.12.007_bib21","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.cllc.2016.12.015","article-title":"Real-world EQ5D health utility scores for patients with metastatic lung cancer by molecular alteration and response to therapy","volume":"18","author":"Labb\u00e9","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.pathol.2025.12.007_bib22","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1186\/s12885-021-08756-x","article-title":"Out-of-pocket medical expenses compared across five years for patients with one of five common cancers in Australia","volume":"21","author":"Rodriguez-Acevedo","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pathol.2025.12.007_bib23","series-title":"The Pharmaceutical benefits Advisory Committee guidelines version 5.0","year":"2016"},{"key":"10.1016\/j.pathol.2025.12.007_bib24","series-title":"Consumer Price Index, Australia March 2025","year":"2025"},{"key":"10.1016\/j.pathol.2025.12.007_bib25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","article-title":"Budget impact analysis\u2014principles of good practice: report of the ISPOR 2012 budget impact analysis Good practice II Task Force","volume":"17","author":"Sullivan","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.pathol.2025.12.007_bib27","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/14737167.2021.1847648","article-title":"Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia","volume":"21","author":"Khoo","year":"2020","journal-title":"Expert Rev Pharmacoecon Outcome. Res"},{"key":"10.1016\/j.pathol.2025.12.007_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0238018","article-title":"Health services costs for lung cancer care in Australia: estimates from the 45 and up study","volume":"15","author":"Goldsbury","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.pathol.2025.12.007_bib29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40273-023-01344-w","article-title":"Exploring the cost effectiveness of a whole-genome sequencing-based biomarker for treatment selection in patients with advanced lung cancer ineligible for targeted therapy","volume":"42","author":"Mfumbilwa","year":"2024","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.pathol.2025.12.007_bib30","article-title":"Cost-effectiveness of next-generation sequencing versus single-gene testing for the molecular diagnosis of patients with metastatic non\u2013small-cell lung cancer from the perspective of Spanish reference centers","volume":"7","author":"Arriola","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.pathol.2025.12.007_bib31","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/14737167.2021.1917386","article-title":"Early technology assessment of using whole genome sequencing in personalized oncology","volume":"21","author":"Simons","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcome. Res"},{"key":"10.1016\/j.pathol.2025.12.007_bib32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.lungcan.2020.07.012","article-title":"Spatial heterogeneity of PD-L1 expression and the risk for misclassification of PD-L1 immunohistochemistry in non-small cell lung cancer","volume":"147","author":"Ben Dori","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.pathol.2025.12.007_bib33","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet."},{"key":"10.1016\/j.pathol.2025.12.007_bib34","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.5858\/arpa.2016-0091-SA","article-title":"Biomarker testing in lung carcinoma cytology specimens: a perspective from members of the Pulmonary Pathology Society","volume":"140","author":"Roy-Chowdhuri","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.pathol.2025.12.007_bib35","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/cncy.22299","article-title":"A new guideline from the College of American Pathologists to improve the adequacy of thoracic small specimens for ancillary studies","volume":"128","author":"Roy-Chowdhuri","year":"2020","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.pathol.2025.12.007_bib36","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/modpathol.2016.228","article-title":"Concurrent fine needle aspirations and core needle biopsies: a comparative study of substrates for next-generation sequencing in solid organ malignancies","volume":"30","author":"Roy-Chowdhuri","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2025.12.007_bib37","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/cncy.21844","article-title":"Accuracy of next-generation sequencing for the identification of clinically relevant variants in cytology smears in lung adenocarcinoma","volume":"125","author":"Baum","year":"2017","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.pathol.2025.12.007_bib38","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3390\/jpm5040470","article-title":"Assessing the costs and cost-effectiveness of genomic sequencing","volume":"5","author":"Christensen","year":"2015","journal-title":"J Pers Med"},{"key":"10.1016\/j.pathol.2025.12.007_bib39","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s40258-024-00927-8","article-title":"Exploratory cost-utility analysis of a 37-gene panel versus usual care to guide therapy for patients with intermediate-risk myeloid malignancies","volume":"23","author":"Lindsay","year":"2025","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.pathol.2025.12.007_bib40","article-title":"Economic analysis of tissue-first, plasma-first, and complementary NGS approaches for treatment-naive metastatic lung adenocarcinoma","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.pathol.2025.12.007_bib41","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1080\/13696998.2024.2314430","article-title":"Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer","volume":"27","author":"Bestvina","year":"2024","journal-title":"Med Econ"},{"key":"10.1016\/j.pathol.2025.12.007_bib42","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrg.2017.108","article-title":"Cost-effectiveness analyses of genetic and genomic diagnostic tests","volume":"19","author":"Payne","year":"2018","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.pathol.2025.12.007_bib43","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jmoldx.2022.04.010","article-title":"Diagnostic value and cost-effectiveness of next-generation sequencing-based testing for treatment of patients with advanced\/metastatic non-squamous non-small-cell lung cancer in the United States","volume":"24","author":"Zou","year":"2022","journal-title":"J Mol Diagn"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302526004472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302526004472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:37:47Z","timestamp":1778852267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302526004472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0031302526004472"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2025.12.007","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness analysis of four sampling and genomic testing strategies for patients with advanced non-small-cell lung cancer in Australia","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2025.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}